Thymosin Alpha 1 Explored for EGFR-Mutated Lung Cancer Treatment
First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy
Abstract
First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy
NCT ID: NCT02906163
Status: UNKNOWN
Sponsor: SciClone Pharmaceuticals…